Ayaka Morimoto

Findings of 18F‐PI‐2620 tau PET imaging in patients with Alzheimer’s disease and healthy controls in relation to the plasma P‐tau181 levels in a Japanese sample

R. Ueda, S. Nakajima, Masaru Mimura, 2022, Neuropsychopharmacology reports.

Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies

M. Jinzaki, M. Mimura, R. Ueda, 2021, Brain communications.

Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management

M. Jinzaki, M. Mimura, R. Ueda, 2022, Neurology.

Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status

K. Takahata, Yasuharu Yamamoto, H. Tabuchi, 2023, Alzheimer's Research & Therapy.